Seer and Korea University launch a study to identify blood-based cancer biomarkers using advanced mass spectrometry and AI analytics. Seer, Inc. and Korea University have launched a groundbreaking ...
Seer, Inc. will present innovative findings at the 21st Annual US Human Proteome Organization (HUPO) Conference in Philadelphia from February 22-26, 2025, where they will highlight advancements in ...
(Nasdaq: SEER), a leader in deep, unbiased proteomic insights, today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office issued a Final Written Decision ...
Hi. My name is Yuko Oku and I'm part of the life science tools and diagnostics team at Morgan Stanley. Before we begin, I'd like to remind our listeners that ...
This featured session will highlight how multi-omic approaches powered by Seer’s Proteograph Product Suite are transforming translational genomics and clinical research. Brendan Keating, PhD, ...
At ASHG, Seer showcased its Proteograph product suite which it claims delivers proteomic insights that complement and strengthen other forms of omics data. Through various sessions at the meeting, the ...
Categorizing patients with cancer by their disease stage can be an important tool when conducting administrative claims-based studies. As claims databases frequently do not capture this information, ...
Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer ...
Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT): A randomized phase II study of gemcitabine and nab-paclitaxel compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results